10 mg
Trade Name
Empamac
Film-coated tablet
Request Type
New Registration
Drug Type
Generic(Multisource) Drug
Approval Date
SFDA Approved Use
Type 2 diabetes mellitus
Empagliflozin is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise
-as monotherapy when metformin is considered inappropriate due to intolerance
-in addition to other medicinal products for the treatment of diabetes
Heart failure
Empagliflozin is indicated in adult patients with heart failure (NYHA class II-IV) independent of left ventricular ejection fraction, with or without type 2 diabetes mellitus:
-to reduce the risk of cardiovascular death and hospitalization for heart failure
-to slow kidney function decline
Chronic kidney disease
Empagliflozin is indicated in adults for the treatment of chronic kidney disease.
Empagliflozin is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise
-as monotherapy when metformin is considered inappropriate due to intolerance
-in addition to other medicinal products for the treatment of diabetes
Heart failure
Empagliflozin is indicated in adult patients with heart failure (NYHA class II-IV) independent of left ventricular ejection fraction, with or without type 2 diabetes mellitus:
-to reduce the risk of cardiovascular death and hospitalization for heart failure
-to slow kidney function decline
Chronic kidney disease
Empagliflozin is indicated in adults for the treatment of chronic kidney disease.